3 recruiting, 3 terminated, 2 completed, 2 withdrawn. 12 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 3, Terminated 3, Completed 2, Withdrawn 2, Active not recruiting 1, Suspended 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Pediatric Brain Tumor: new trials by email Literature Review of Pediatric Brain Tumor trials Research Report on Pediatric Brain Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults GPC2-CAR T cells, Fludarabine, Cyclophosphamide - Medulloblastoma, Central Nervous System Embryonal Tumor | Phase 1 | Recruiting | Stanford University | 18 | 2025-08-28 | 2026-10-09 |
| Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells, Implantation, Magnetic Resonance Imaging (MRI) - Pediatric Brain Tumor, Recurrent Pediatric Brain Tumor | Phase 1 | Suspended | Sabine Mueller, MD, PhD | 24 | 2024-05-31 | 2026-04-24 |
| Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Dapagliflozin, Carmustine, Topotecan - Pediatric Brain Tumor, Pediatric Solid Tumor | Phase 1 | Recruiting | Washington University School of Medicine | 20 | 2023-04-03 | 2026-06-10 |
| Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors Personalized peptide vaccine, Poly ICLC, Peripheral blood draw - Pediatric Brain Tumor | Phase 1 | Withdrawn | Washington University School of Medicine | 2021-09-30 | 2021-05-25 | |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG Marizomib, Panobinostat - Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma | Phase 1 | Terminated | Dana-Farber Cancer Institute | 4 | 2020-08-10 | 2024-02-15 |
| 9-ING-41 in Pediatric Patients With Refractory Malignancies. 9-ING-41, Irinotecan, Temozolomide - Refractory Cancer, Refractory Neoplasm | Phase 1 | Terminated | Actuate Therapeutics Inc. | 40 | 2020-06-05 | 2025-07-17 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors G207 - Neoplasms, Brain, Glioblastoma Multiforme | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2019-09-12 | 2026-09-04 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas CLR 131 - Pediatric Solid Tumor, Pediatric Lymphoma | Phase 1 | Active not recruiting | Cellectar Biosciences, Inc. | 30 | 2019-04-30 | 2026-10-01 |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma CMV-DCs with GM-CSF, Td (tetanus toxoid) - Glioblastoma, Malignant Glioma | Phase 1 | Completed | Gary Archer Ph.D. | 11 | 2018-10-05 | 2021-01-28 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG) - Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Terminated | Alaunos Therapeutics | 6 | 2017-09-26 | 2025-08-12 |
| Valproic Acid in Childhood Progressive Brain Tumors Valproic Acid - Pediatric Brain Tumor, Glioma | Phase 1 | Withdrawn | Medical University of South Carolina | 2013-05-01 | 2015-05-22 |
Glioblastoma (6) · Glioma (6) · Medulloblastoma (6) · Astrocytoma (5) · Neoplasms (5) · Neuroectodermal Tumors, Primitive (5) · Brain Neoplasms (4) · Diffuse Intrinsic Pontine Glioma (4) · Rhabdoid Tumor (4) · Ependymoma (3) · Neoplasms, Neuroepithelial (3) · Recurrence (3) · Central Nervous System Neoplasms (2) · Choroid Plexus Carcinoma (2) · Gliosarcoma (2)
Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Neoplasms, Nerve Tissue (8) · Neuroectodermal Tumors (8) · Brain Diseases (7) · Central Nervous System Diseases (7) · Neoplasms by Site (7) · Neoplasms, Germ Cell and Embryonal (7) · Nervous System Diseases (7) · Nervous System Neoplasms (7) · Central Nervous System Neoplasms (6) · Neoplasms, Neuroepithelial (6) · Infratentorial Neoplasms (5) · Neoplasms (5) · Brain Neoplasms (4)
Cyclophosphamide (3) · Topotecan (2) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · CLR1404 (1) · Carmustine (1) · Cell Count (1) · Diphtheria Toxoid (1) · Drug Implants (1) · Filgrastim (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Irinotecan (1) · Magnetic Resonance Spectroscopy (1) · Panobinostat (1)
Washington University School of Medicine (2) · Actuate Therapeutics Inc. (1) · Alaunos Therapeutics (1) · Cellectar Biosciences, Inc. (1) · Dana-Farber Cancer Institute (1) · Gary Archer Ph.D. (1) · M.D. Anderson Cancer Center (1) · Medical University of South Carolina (1) · Sabine Mueller, MD, PhD (1) · St. Jude Children's Research Hospital (1) · Stanford University (1)
United States (11) · Australia (1) · Canada (1)
Amy L Bredlau, MD (1) · Andrew Cluster, M.D. (1) · Daniel Landi, MD (1) · Giles W. Robinson, MD (1) · Gregory Friedman, MD (1) · Jarrod Longcor (1) · Jaymes Holland (1) · Joshua Rubin, M.D., Ph.D. (1) · Katherine Ryan, DO (1) · Katherine Warren, MD (1) · Sabine Mueller, MD, PhD (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 31101621, PMID 31533931, PMID 31831767, PMID 31882719